A Glimpse Into The Expert Outlook On Arcutis Biotherapeutics Through 5 Analysts

Analysts' ratings for Arcutis Biotherapeutics ARQT over the last quarter vary from bullish to bearish, as provided by 5 analysts.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $19.6, with a high estimate of $20.00 and a low estimate of $19.00. This current average reflects an increase of 3.16% from the previous average price target of $19.00.

Diving into Analyst Ratings: An In-Depth Exploration

A clear picture of Arcutis Biotherapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Arcutis Biotherapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Arcutis Biotherapeutics compared to the broader market.
• Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Arcutis Biotherapeutics's stock. This examination reveals shifts in analysts' expectations over time.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Arcutis Biotherapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Arcutis Biotherapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About Arcutis Biotherapeutics

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Arcutis Biotherapeutics's Financial Performance

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Revenue Growth: Arcutis Biotherapeutics displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 17.44%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Arcutis Biotherapeutics's net margin excels beyond industry benchmarks, reaching -92.81%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Arcutis Biotherapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -24.21%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): Arcutis Biotherapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -9.42%, the company may face hurdles in achieving optimal financial returns.

Debt Management: Arcutis Biotherapeutics's debt-to-equity ratio surpasses industry norms, standing at 1.33. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

How Are Analyst Ratings Determined?

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.